Tharimmune, Inc. (THAR)

3.5300 +0.3200 (+9.97%) 收市：04:00PM EDT

Tharimmune, Inc.

1200 Route 22 East
Suite 2000
Bridgewater, NJ 08807
United States
908 955 3140
https://www.tharimmune.com

版塊: Healthcare
行業: Biotechnology
全職員工: 2

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Randy D. Milby MBA	President, Chairman & CEO	593.75k	無	1954
Mr. Sireesh Appajosyula Pharm.D.	COO & Director	584.8k	無	1976
Mr. Thomas P. Hess CPA, MBA	Chief Financial Officer	無	無	1964

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

公司管治

截至 無 止，Tharimmune, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。